Home › Occupations › Biochemists and Biophysicists › San Carlos, CA
Biochemists and Biophysicists in San Carlos, CA: H-1B salaries
35 labor condition applications for this occupation with a work site in San Carlos, CA. Median offered base salary $117,700; middle half $108,750–$165,000.
By wage level
| Wage level | Median salary |
|---|---|
| Level I (entry) | $90,000 |
| Level II (qualified) | $113,000 |
| Level III (experienced) | $165,000 |
| Level IV (fully competent) | $174,006 |
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Employers
| Employer | LCAs | Median salary |
|---|---|---|
| Vaxcyte, Inc. | 19 | $152,300 |
| Nautilus Subsidiary, Inc | 5 | $128,649 |
| Nautilus Biotechnology, Inc. | 2 | $105,000 |
| Synthetic Design Lab, Inc. | 2 | $116,441 |
| LakePharma, Inc. | 1 | $102,000 |
| Nautilus Subsidary, Inc | 1 | — |
| Clear Labs, Inc. | 1 | $105,000 |
| Aperture Therapeutics, Inc. | 1 | $140,000 |
| Acrobat Genomics Inc. | 1 | $88,680 |
| Ridge Biotechnologies, Inc. | 1 | $90,000 |
| Acrocyte Therapeutics Inc. | 1 | $115,357 |
Job titles
- Research Associate III3
- Senior Scientist, Analytical Development3
- Scientist I2
- Associate Scientist2
- Associate Engineer II, MSAT2
- Senior Scientist2
- Senior Scientist I1
- Group Leader, Formulation Development1
- Associate Scientist - II (Protein)1
- Group Leader, Drug Product1
- Associate Scientist II, Conjugation Development1
- Scientist II, Drug Discovery1
- Senior Scientist, Drug Product Analytics1
- Associate Engineer I1
- Associate Scientist I, Research1
H-1B sponsors in San Carlos, CA →
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).